Amendments to the Claims

1-2. (Cancelled)

- **3. (Original)** A pharmaceutical composition used for treatment or prevention of brain injury comprising an antagonist for prostaglandin D receptor as an effective ingredient.
- **4. (Original)** The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is (±)-3-benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2- hydroxyethylamino)-hydantoin, (+)-(3R)-3-(4-fluorobenzenesulfonamide)-1,2,3,4-tetrahydrocarbazol-9- propionic acid, (Z)-7-[(1R,2R,3S,5S)-2-(5- hydroxybenzo[b]thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid, (Z)-7-[(1R,2R,3S,5S)-2-(benzo[b]- thiophene-3-ylcarbonylamino)-10-norpinan-3-yl]hepta-5-enoic acid and pharmaceutically acceptable salt thereof and hydrate thereof.
- **5.** (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (I)

$$\begin{array}{c|c}
H & S \\
 & R \\
\hline
V & O \\
 & CH=CH & COOX
\end{array} (I)$$

(wherein,

$$(\mathbf{Y})$$
 is (\mathbf{A}) or (\mathbf{B})

R is hydrogen, alkyl, alkoxy, halogen, hydroxyl, acyloxy or optionally substituted arylsulfonyloxy; X is hydrogen or alkyl; and a double bond of an α -chain is in an E-

configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

6. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA)

(wherein R and X have the same meanings as defined already and a double bond of an α -chain is in an E-configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

7. (Original) The pharmaceutical composition according to claim 3, wherein the antagonist for a prostaglandin D receptor is a compound represented by the formula (IA-a)

(wherein R and X have the same meanings as defined already and a double bond of an α -chain is in an E-configuration or a Z-configuration) or a pharmaceutically acceptable salt or a hydrate thereof.

8-9. (Cancelled)

- **10.** (Original) A method for treatment of brain injury comprising administration of a prostaglandin D receptor antagonist of an effective dose.
- 11. (Original) A use of a prostaglandin D receptor antagonist for the manufacture of a drug for treatment of brain injury.

12-13. (Cancelled)